A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)
Sponsors
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Janssen Research & Development, LLC
Conditions
Healthy
Phase 1
A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Volunteers
CompletedNCT01454622
Start: 2011-09-30End: 2011-11-30Updated: 2013-05-06
A Study to Assess the Bioequivalence of Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers
CompletedNCT01463228
Start: 2011-09-30End: 2012-01-31Updated: 2012-08-22
A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg/850 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin IR Tablets (2 x 850 mg) in Healthy Volunteers
CompletedNCT01518712
Start: 2011-09-30End: 2011-11-30Updated: 2012-08-29